Sign In

QOPI
ASCO QOPI

Report on evidence-based quality measures and receive performance scores via the Quality Oncology Practice Initiative (QOPI®).

Sign In

ASCO Connection

Effective May 2021, The Oncology Practice Insider newsletter consolidated with the ASCO Connection newsletter.

ASCO provides the latest news, information, and educational tools to assist with the successful management of oncology practice and the delivery of high-quality patient care, including updates on ASCO programs, services, and cancer-related health policy, Medicare news, and billing and coding best practices. The biweekly ASCO Connection newsletter features the latest information on ASCO programs and resources for every member of the oncology community, including information tailored for practice administrators and practice leaders. Subscribe to the ASCO Connection newsletter for Practice News updates.

Date

FDA Approves Omidubicel to Reduce Time to Neutrophil Recovery and Infection in Patients with Hematologic Malignancies

On April 17, 2023, the Food and Drug Administration approved omidubicel-onlv (Omisirge, Gamida Cell Ltd.) for use in adult and pediatric patients (12 years and older) with hematologic malignancies who are planned for umbilical cord blood transplantation following myeloablative conditioning to reduce the time to neutrophil recovery and the incidence of infection. Read more. 

FDA Approves Dabrafenib With Trametinib For Pediatric Patients With Low-grade Glioma With a BRAF V600E Mutation

On March 16, 2023, the Food and Drug Administration approved dabrafenib (Tafinlar, Novartis) with trametinib (Mekinist, Novartis) for pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. The FDA also approved new oral formulations of both drugs suitable for patients who cannot swallow pills. Read more. 

FDA Expands Early Breast Cancer Indication For Abemaciclib With Endocrine Therapy

On March 3, 2023, the Food and Drug Administration (FDA) approved abemaciclib (Verzenio, Eli Lilly and Company) with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of recurrence. Read more.   

COVID-19 Public Health Emergency (PHE) New Overview Fact Sheet

As part of the Centers for Medicare & Medicaid Services’ (CMS) ongoing efforts to provide up-to-date information to prepare for the end of the Public Health Emergency (PHE) for COVID-19 on May 11, 2023, CMS is providing a new overview fact sheet on CMS Waivers, Flexibilities, and the Transition Forward from the COVID-19 Public Health Emergency.

FDA Approves Pembrolizumab as Adjuvant Treatment For Non-Small Cell Lung Cancer

On January 26, 2023, the Food and Drug Administration (FDA) approved pembrolizumab (Keytruda, Merck) for adjuvant treatment following resection and platinum-based chemotherapy for stage IB (T2a ≥4 cm), II, or IIIA non-small cell lung cancer (NSCLC). Read more.  

FDA Grants Accelerated Approval to Pirtobrutinib For Relapsed or Refractory Mantle Cell Lymphoma

On January 27, 2023, the Food and Drug Administration (FDA) granted accelerated approval to pirtobrutinib (Jaypirca, Eli Lilly and Company) for relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor. Read more. 

Reminder: 2022 MIPS Data Submission Period Now Open Through March 31

The Centers for Medicare & Medicaid Services (CMS) has opened the data submission period for Merit-based Incentive Payment System (MIPS) eligible clinicians who participated in the 2022 performance year of the Quality Payment Program (QPP). Data can be submitted and updated until 8:00 PM ET on March 31, 2023. Clinicians can go to the Quality Payment Program sign-in page and sign in using your QPP access credentials then submit your MIPS data for the 2022 performance year or review the data reported on your behalf by a third party.

Reminder: CMS Extended the MIPS Extreme and Uncontrollable Circumstances Exception Application Deadline Until March 3

For the 2022 performance year, the Centers for Medicare & Medicaid (CMS) continue to use the Merit-based Incentive Payment System (MIPS) Extreme and Uncontrollable Circumstances (EUC) Exception policy to allow individuals, groups, virtual groups, and Alternative Payment Model (APM) Entities to submit an application requesting reweighting of MIPS performance categories due to the COVID-19 public health emergency (PHE).